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Abstract
Background: Environmental tobacco smoke (ETS) has adverse effects on the health of asthmatics, however the harmful
consequences of ETS in relation to asthma severity are unknown.
Methods: In a multicenter study of severe asthma, we assessed the impact of ETS exposure on morbidity, health care
utilization and lung functions; and activity of systemic superoxide dismutase (SOD), a potential oxidative target of ETS that is
negatively associated with asthma severity.
Findings: From 2002–2006, 654 asthmatics (non-severe 366, severe 288) were enrolled, among whom 109 non-severe and
67 severe asthmatics were routinely exposed to ETS as ascertained by history and validated by urine cotinine levels. ETS-
exposure was associated with lower quality of life scores; greater rescue inhaler use; lower lung function; greater
bronchodilator responsiveness; and greater risk for emergency room visits, hospitalization and intensive care unit
admission. ETS-exposure was associated with lower levels of serum SOD activity, particularly in asthmatic women of African
heritage.
Interpretation: ETS-exposure of asthmatic individuals is associated with worse lung function, higher acuity of exacerbations,
more health care utilization, and greater bronchial hyperreactivity. The association of diminished systemic SOD activity to
ETS exposure provides for the first time a specific oxidant mechanism by which ETS may adversely affect patients with
asthma.
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Introduction
Asthma is a chronic inflammatory disorder of the airways
involving complex interactions of cells and mediators, which lead
to oxidative and nitrosative modifications of airway proteins
[1,2,3,4,5] that are relevant to the initiation and maintenance of
inflammation [3,4,5,6,7]. The protein modifications occur not
only as a result of endogenous inflammatory processes in asthma
but also from inhalation of exogenous environmental oxidants.
Environmental tobacco smoke (ETS), a mixture of gases and
particles from the burning cigarette and exhaled mainstream
smoke [8], contains more than 1014 oxidative molecules per puff of
smoke, including both nitric oxide and superoxide [9,10]. The
importance of ETS in the etiology of asthma in children has been
established. Parental smoking is associated with poorer lung
functions in asthmatic children, and the relative risk of asthma is
greater in children exposed to cigarette smoking by both parents
compared with smoking of neither parent [11,12,13,14,15]. Yet
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the evidence regarding effects of ETS on asthmatic adults is sparse,
despite the fact that many asthmatic adults report ETS as a major
exacerbating factor [14,16,17,18,19].
Epidemiologic studies suggest that ETS leads to greater severity
of adult asthma [20,21,22,23,24,25,26,27]. Experimental studies
on the acute effect of ETS in adult asthma supports its
contribution to exacerbation of asthma [28,29]. However, effects
in relation to asthma severity are unknown; and the mechanisms
causing decline in ETS-exposed asthmatics are unclear. Evidence
suggests that oxidant excess and diminished antioxidant capacity
in the airway are closely associated with defining features of
asthma including airflow limitation and hyper-reactivity
[3,6,30,31,32]. Worsening airflow obstruction and airway remod-
eling events are closely associated with loss of antioxidant capacity
of the superoxide dismutases (SOD; EC 1.15.1.11), which catalyze
the reaction of superoxide to hydrogen peroxide [6,30,31,32]. The
mechanisms for loss of activity appear to be related to oxidative
protein modifications, including the nitration and chlorination of
tyrosine residues in the MnSOD [6,7,31,33,34,35,36]. Here, we
hypothesized that ETS has quantifiable adverse effects on the
health of well-established asthmatic individuals. In addition to
quantifying the impact of ETS on morbidity, health care
utilization and lung function, we also investigated potential
mechanisms of effect by assessing systemic SOD activity in
relation to ETS exposure.
Methods
The study was conducted as part of the multicenter study
through the NHLBI Severe Asthma Research program (SARP).
The study includes 654 participants enrolled at 10 sites between
2002–2006. The protocol was approved by the Cleveland Clinic
Institutional Review Board, and all procedures were monitored by
an independent Data Safety Monitoring Board. All participants
gave written informed consent.
Participant Selection in SARP
Asthma severity (non-severe and severe asthma) was categorized
as defined by the proceedings of the American Thoracic Society
Workshop on Refractory Asthma [37]. Current smokers and
former smokers with greater then 5 pack-year history were
excluded.
Study Visits
Participants were interviewed by SARP administrative staff at
each clinical site [Wake Forest University, National Jewish
Medical and Research Center, Imperial College, London (U.K),
University of Wisconsin, Cleveland Clinic, Washington University
St Louis, Emory University, Brigham & Women’s Hospital,
University of Pittsburgh, and University of Virginia]. The
questionnaires included demographics, medical co-morbidities,
smoking, medical and medication history [38]. Asthma quality of
life, asthma exacerbations and health care utilization were assessed
by using the Asthma Control Questionnaire (ACQ) developed by
Juniper, et al [39]. Exposure to ETS was based on the question:
‘‘Are you exposed to second hand smoke?’’
Pulmonary function testing was performed on an automated
spirometer consistent with American Thoracic Society standards
with National Health and Nutrition Examination Survey
(NHANES III) reference. Subjects with a FEV1,55% predicted
were excluded from methacholine testing due to safety concerns.
Blood was collected in a serum separation tube and centrifuged
at 1500 rpm for 10 minutes. Serum was aliquoted and stored at
280 C until used in analysis.
Antioxidant measurements
SOD activity was determined by the rate of reduction of ferri-
cytochrome c, with one unit (U) of SOD activity defined as the
amount of SOD required to inhibit the rate of cytochrome c
reduction by 50% in the presence of a superoxide-generating system
[6]. Serum cotinine levels are proportionate to the amount of
tobacco smoke exposure, including secondary smoke inhalation. In
this network study, not all subjects’ serum was available for study.
Due to limitation of serum, we were not able to measure SOD
activity in all asthmatic subjects. Non -severe and severe asthmatics
are proportional in number among all subjects enrolled in the study
and within the subgroups with SOD measures. Importantly, there
was not a selective loss of a specific population within any grouping.
Glutathione peroxidase activity (GPx), total glutathione
(GSH+GSSG) and eGPx protein were determined as previously
described [40]. Serum cotinine was measured by high-performance
liquid chromatography atmospheric pressure chemical ionization
tandem mass spectrometry as previously described [41].
Statistical Analysis
Patient characteristics, lung function, quality of life scores,
medication use, and SOD measures were summarized within the
subsets of control subjects and asthmatic subsets for those
participants with and without ETS. Normally distributed quan-
titative variables were summarized using means and standard
deviations, non-normally distributed variables as median (inter-
quartile ranges), and categorical variables were summarized by
their observed frequencies and percents within the participant
subsets. Participants with and without ETS exposure within the
subsets were compared with respect to quantitative and categorical
variables using T-tests and Chi-square tests, respectively.
Wilcoxon rank sum tests were a non-parametric alternative for
comparisons with respect to quantitative or ordinal variables, and
Fisher’s exact test was an alternative to the Chi-square test in the
presence of low expected frequencies in the chi-square calcula-
tions.
Logistic regression models were used to calculate odds ratios
(ORs) of abnormal lung function (FEV1/FVC below 70,
FEV1below 80%, change in FEV1 above 12% and methacholine
PC20 below 3.1 mg/ml), morbidity and medication, with respect
to ETS. The logistic models, and the two-group comparison T-test
models, were extended to include the interaction between asthma
severity and ETS to determine if ETS associations should be
described within severe and non-severe asthmatics separately.
Multivariable regression models were constructed to study the
relationships between variables and ETS and potential confound-
ers. Age, body mass index, sex, and race (African heritage vs. non-
African heritage) were included in all models as covariates. For a
given quantitative or ordinal study variable chosen as the
dependent variable, interactions were considered among the
following variables: asthma category, ETS, sex, and race.
Sequentially, likelihood ratio tests for the presence of a 4-way
interaction, then the set of 3-way interactions, then the set of 2-
way interactions were performed. If none of these sets of
interactions were deemed significant, at a level of 0.10, then a
model without interactions was considered the final model. In the
presence of interactions up to a certain degree, specific interactions
of that degree were then inspected, and non-significant specific
interactions at the 0.10 levels were removed together to produce a
final model. Associations between ETS and dependent variables
were estimated from the models with 95% confidence intervals.
Analyses were conducted with JMP IN 5.1 (SAS System, SAS
Institute, Cary, NC) and R version 2.4.1. (R Foundation for
Statistical Computing, Vienna, Austria).
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Results
Participants
The study participants included 366 non-severe asthmatics and
288 severe asthmatics. The age range distribution was as follow: 95
children (,20 yrs), 316 young adults (20–40 yrs), 232 age (40–
65 yrs,) and 11 elderly (.65 yrs). None were current smokers but
102 were former smokers with an average of years 1561 since they
last smoked and less than 2.460.4 pack/years. All analysis is
shown for the entire population. Analyses were also performed in
asthmatics excluding former smokers with similar findings. The
age range was between 6 and 79 years. Participants classified as
severe asthmatics were older and shorter as compared to non-
severe asthmatics (TABLE 1). A substantial portion of the non-
severe asthmatic group exposed to ETS was of African heritage
(41.3%) as compared to the ETS unexposed group (23.4%)
(TABLE 1). Other participant characteristics are shown in
TABLE 1.
Determination of Environmental Tobacco Smoke
A total of 176 asthmatic participants (26.8%) answered
affirmatively to the question, ‘‘Are you exposed to second hand smoke?’’;
with regard to asthmatic classification, 109 non-severe asthmatics
(30%) and 67 severe asthmatics (23%) answered affirmatively. Of
the 71 asthmatic children (ages from 6–18), 13 children were
exposed to ETS. When asked if participants experienced asthma
symptoms when exposed to ETS, 72% of the 654 asthmatic
participants reported asthma symptoms as a result of being
exposed to ETS. ETS exposed participants had cotinine levels that
are considered low to moderate passive smoking (median of
Cotinine (ng/ml): 0.18, IQR, 0.056–0.69). Cotinine was not
detectable in asthmatics whom reported no-exposure to ETS.
Impact of ETS exposure on asthma
Quality of life. The Juniper questionnaire data suggest
Asthmatic participants exposed to ETS had a lower total quality
of life score than non-ETS-exposed asthmatics. Perhaps
predictably, the greatest decrease is observed in the
environmental and symptom domains. The association of ETS
exposure and worse symptom scores was most pronounced in non-
severe asthmatics, which are not on regular corticosteroids, which
suggests that corticosteroids may influence the perception of ETS
effect (TABLE 2).
Lung function. Non-severe asthmatics exposed to ETS had
poorer lung function, as confirmed by a significantly lower %FEV1
and FEV1/FVC (FEV1 24.14, 95%CI. 28.09 to 20.20; FEV1/
Table 1. Baseline Characteristics of Study Participants.
Characteristic Non-severe asthma Severe asthma
ETS (N=109) Non-ETS (N=257) ETS (N=67) Non-ETS (N=221)
Age (yrs) 31.661.2 32.060.8 37.961.7 39.561.1
Male Sex–No. (%) 44 (40) 81 (31) 21 (31) 89 (40)
Caucasian-No. (%) 55 (50.5) 182 (70.8)* 37 (55.2) 141 (63.8)
African-No. (%) 45 (41.3) 60 (23.4)* 24 (35.8) 61 (27.6)
Asian-No. (%) 2 (1.8) 3 (1.2) 1 (1.5) 7 (3.2)
Multiple Race-No. (%) 4 (3.7) 7 (2.7) 1 (1.5) 1 (0.5)
Others-No. (%) 3 (2.7) 4 (1.5) 4 (6.0) 10 (4.5)
Unknown-No. (%) 1 (0.4) 1 (0.5)
Weight (kg) 80.562.5 79.461.5 84.162.8 82.561.8
Height (cm) 167.161.1 167.360.7 165.161.5 165.060.8
Body Mass Index 28.660.7 28.368.1 30.760.9 29.960.6
Family History of Allergic disease
Asthma-No. (%) 72 (66.0) 156 (60.7) 46 (68.7) 125 (56.7)
Hay fever/Allergies-No. (%) 85 (78.0) 205 (80.0) 46 (68.7) 161 (72.9)
Eczema-No. (%) 30 (27.5) 79 (30.7) 21 (31.4) 74 (33.5)
Pets-No. (%) 61 (55.0) 183 (71.2)* 37 (55.2) 104 (47.1)
High Dose Corticosteroid-No. (%) 55 (50.5) 156 (60.7) 67 (100) 221 (100)
Atopy Pos-No. (%) 4.060.3 3.660.2 2.760.3 2.960.2
IgE 343.5660.0 225.1619.1 472.46143.1 402.0671.7
Total Cells - 106 6.760.2 6.660.1 7.760.4 7.960.2
Neutrophils (%) 55.661.1 58.462.2 60.162.0 61.061.0
Lymphocytes (%) 32.661.0 34.261.7 28.761.5 27.660.8
Monocytes (%) 6.860.2 6.860.3 6.160.4 6.660.4
Eosinophils (%) 4.460.3 4.060.2 4.560.8 4.160.3
Basophils (%) 0.560.05 0.560.03 0.460.06 0.460.04
*Significant difference in Caucasian and African race among ETS and non-ETS group in Non-severe asthma. The P-value (P,0.05) is calculated by the Pearson chi-square
test. High dose corticosteroid defined as twice a week inhaled corticosteroids and/or weekly systemic corticosteroids. ‘‘Unkown’’ does not wish to declare or does not
know his/her ethnicity.
doi:10.1371/journal.pone.0018574.t001
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FVC 20.03, 95%CI. 20.06 to 20.01). ETS was associated with
greater airway reactivity in all asthmatics exposed to ETS as
compared to asthmatics not exposed. Non-severe asthmatics with
ETS exposure had greater airflow reactivity to bronchodilator
(%DFEV1 3.8, 95%CI. 0.97 to 6.2, p = 0.009). Severe asthmatics
exposed to ETS had greater airway hyperresponsiveness to
provocative challenge with methacholine (PC20 22.88, 95%CI.
24.41 to 21.24, p = 0.001) than those not exposed.
Likelihood ratio tests confirmed that ETS exposure was
associated with significantly lower lung function, Specifically,
non-severe asthmatics with ETS-exposure had an estimated 2.1
times higher odds for worse airflow obstruction (FEV1/
FVC,70%) than non-exposed non-severe asthmatics (OR 2.1,
95%CI. 1.3–3.5, p = 0.003). ETS-exposure resulted in 1.7 fold
greater likelihood of significant airflow reactivity, as measured
by the change in FEV1 with bronchodilator .12% (OR 1.7,
95% CI. 1.0 to 2.7, p = 0.04). Severe asthmatics exposed to ETS
had an estimated 15.3 times higher likelihood for more severe
airway hyperreactivity (PC 20,3.1 mg/ml) as compared to
non-exposed severe asthmatics (OR 15.3, 95%CI. 3 to 282,
p = 0.0002).
Health care utilization. ETS exposure was associated with
increased health care utilization, particularly among non-severe
asthmatics: in this group, it increased risk for urgent care visits,
emergency room visits, overnight hospital stays, intensive care unit
admissions, and assisted ventilation (TABLE 3). ETS had no
influence on health care utilization among severe asthmatics, but
this population was pre-defined for selection into the severe
category based upon clinical criteria that include poor lung
functions, greater symptoms and health care utilization. Thus, the
potential adverse effects of ETS may have been more difficult to
discern in this population.
Medications. ETS exposure was associated with increased
utilization of rescue medication (TABLE 3). The greater use of
rescue inhaler is consistent with the greater perception of symptoms
by asthmatics exposed to ETS, the greater bronchial response to b-
agonist of ETS-exposed asthmatics, and the greater bronchial
hyperreactivity of ETS-exposed severe asthmatics. The greater use
Table 2. Quality of Life.
Non-Severe Asthma Severe Asthma
Non-ETS
(N=236)
ETS
(N=105)
Difference
(95% C. I.) P Value
Non-ETS
(N=195)
ETS
(N=63)
Difference
(95% C. I.) P Value
Total Quality of Score
High Dose Corticosteroid: yes 4.9 (0.1) 4.7 (0.2) 20.2 (20.6 to 0.2) 0.35 4.1 (0.1) 3.7 (0.2) 20.4 (20.72 to 20.01) 0.04
High Dose Corticosteroid: no 5.3 (0.1) 4.6 (0.2) 20.6 (21.0 to 20.2) 0.002
Component Score
Activity 5.0 (0.08) 4.7 (0.12) 20.3 (20.6 to 20.04) 0.02 4.0 (0.1) 3.9 (0.2) 20.2 (20.5 to 0.2) 0.36
Emotional 5.1 (0.1) 4.7 (0.16) 20.4 (20.8 to 20.02) 0.04 3.9 (0.1) 3.6 (0.2) 20.3 (20.8 to 0.1) 0.17
Environmental 4.9 (0.1) 4.4 (0.10) 20.5 (20.8 to 20.2) 0.003 4.2 (0.1) 3.5 (0.2) 20.7 (21.14 to 20.29) 0.001
Symptom
High Dose Corticosteroid: yes 4.9 (0.1) 4.8 (0.2) 20.1 (20.5 to 0.3) 0.63 4.0 (0.1) 3.6 (0.1) 20.4 (20.8 to 20.03) 0.03
Dose Corticosteroid: no 5.3 (0.1) 4.5 (.0.2) 20.7 (20.3 to 21.2) 0.001
Values are means (SE). High dose corticosteroid defined as .twice a week inhaled corticosteroids and/or weekly systemic corticosteroids. All severe asthmatics were on
high dose corticosteroids by definition of severity. For non-severe asthmatics, means (SE) shown relative to dose of corticosteroid for those values that are different by
corticosteroid dose (p,0.05).
doi:10.1371/journal.pone.0018574.t002
Table 3. Hospitalizations and Medications.
Non-Severe Asthma Severe Asthma
Non-ETS
(N=252) ETS (N=108)
Odd Ratio
(95% C. I.) P Value
Non-ETS
(N=211) ETS (N=65)
Odd Ratio
(95% C. I.) P Value
ICU Admission 11 (4.4) 19 (17.6) 4.7 (2.2 to 10.5) ,0.001 95 (44.8) 24 (36.9) 0.7 (0.4 to 1.3) 0.25
Night in Hospital 69 (27.1) 40 (37.7) 1.6 (1.0 to 2.6) 0.04 163 (75.8) 55 (82.1) 1.5 (0.7 to 3.0) 0.27
Urgent Care visit due to asthma 51 (20.0) 32 (30.2) 1.8 (1.0 to 2.9) 0.03 130 (61.0) 40 (59.7) 0.9 (0.5 to 1.7) 0.84
Assisted Ventilation 5 (2.0) 11 (10.4) 5.8 (21. to 18.9) ,0.001 42 (20) 18 (26.9) 1.5 (0.8 to 2.8) 0.24
ER visit for breathing problem 31 (12.2) 26 (23.9) 2.3 (1.3 to 4.0) 0.006 103 (47.7) 33 (49.3) 1.1 (0.6 to 1.8) 0.82
Use of rescue Inhaler
.once a month 156 (60.70) 80 (73.4) 1.8 (1.1 to 3.0) 0.01 180 (82.2) 62 (92.5) 2.6 (1.0 to 7.9) 0.03
weekly or more 108 (42.02) 59 (54.1) 1.6 (1.0 to 2.7) 0.03 161 (73.9) 56 (83.6) 1.8 (0.9 to 3.8) 0.09
All data are presented in No (%). Intensive Care Unit (ICU), Emergency Room (ER).
doi:10.1371/journal.pone.0018574.t003
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of rescue inhaler by ETS-exposed asthmatics, and in particular the
severe asthmatics that are on maximal medical therapy, indicates an
adverse effect of ETS exposure on asthma control.
Antioxidant SOD Activity and ETS exposure
Serum SOD activity was lower in ETS-exposed asthmatic subjects
than in non-exposed asthmatic subjects (SOD U/ml serum: non-ETS
asthma (n=342), 18.260.6; ETS asthma (n=136), 14.76
0.9;p=0.04) (FIGURE 1). As previously reported [6,30], SOD
concentrations were particularly low in severe asthma subjects,
blunting the difference between ETS-exposure and non-ETS
exposure in this group; and ETS exposure therefore had the most
noticeable impact on SOD activity in non-severe asthmatics (SOD
activity U/ml serum in non-severe asthma: non-ETS (n=186),
17.760.9, ETS (n=82), 14.861.0, p=0.02). Of note, we have
previously reported in a smaller cohort (N=135) of this study
population that asthmatics have ,2-fold lower levels of serum SOD
activity as compared to non-asthmatic healthy controls [30].
Environmental tobacco smoke exposure does not seem to alter the
glutathione system (total glutathione levels, glutathione peroxidase
activity or the extracellular glutathione peroxidase protein) in
asthmatics. Glutathione [GSH mM: non-ETS asthma (n=107),
1.560.1, ETS asthma (n=46) 1.460.1; p=0.65], glutathione
peroxidase activity [GPx mU/ml: non-ETS asthma (n=66),
0.0960.002, ETS asthma (n=66) 0.0960.003; p=0.66], and
extracellular glutathione peroxidase protein [eGPx ng/ml: non-ETS
asthma (n=96) 35.961.5, ETS asthma (n=44) 32.863.0; p=0.30]
are similar among ETS and non-ETS asthmatic subjects in this study.
Multivariable Models and ETS
Since age, gender, race and body mass index influence lung
functions and quality of life, we applied a multivariable model to
evaluate ETS effect in relation to these covariates. Despite their
potential influences, these factors, including age, had no determin-
able impact on the associations between ETS and either quality of
life or lung function. Similarly there is no association between SOD,
quality of life, lung functions and age, and no detected ETS/Age
interaction. On the other hand, modeling of SOD revealed a
significant set of interactions, with P,0.001 for an overall test of the
6 two-way interactions formed by asthma severity, gender, race, and
ETS. The implication of the interactions is that the association
between ETS and SOD should be estimated within individual
combinations of Gender and Race. Based on the model parameters,
ETS exposure was associated with the lowest SOD activity for
females of African heritage (estimated mean decrease 6.67, 95%CI.
2.73 to 10.6), which was in greatest contrast to the result for males of
non-African heritage (Figure 2). The finding of greatest impact of
ETS upon SOD activity in African asthmatic women suggests that
the ETS-exposure may disproportionately affect this population
independent of age and asthma severity.
Discussion
This large study of a well-characterized asthma cohort provides
evidence that ETS-exposure of asthmatics is associated with
poorer quality of life scores, increased health care utilization and
greater abnormalities in lung function. Indeed, those asthma
patients traditionally characterized as non-severe were significantly
closer to a severe phenotype if they were exposed to ETS. Taken
together, these observations identify that ETS is an environmental
factor that contributes to severity of asthma.
Etiological studies of adults have found an increased risk of
asthma in relation to exposure to ETS [12,15,42,43]. The Swiss
Study on Air Pollution and Lung Diseases in Adults (SAPALDIA)
suggests that the association of ETS and wheezing is dose-
dependent [42]. Similarly, the European Community Respiratory
Health Survey (ECRHS) and the Studio Epidemiologico su
Ambiente e salute nelle donne (SEASD) identify associations
between ETS and respiratory symptoms and/or diseases [14,44].
Figure 1. Analysis of total SOD activity in all asthmatics
exposed to ETS or non-ETS. Asthmatic subjects exposed to ETS have
significantly lower SOD activity (p = 0.04).
doi:10.1371/journal.pone.0018574.g001
Figure 2. Model-estimated environmental tobacco smoke (ETS)
effects on superoxide dismutase (SOD) activity. ETS exposure
was associated with the lowest SOD activity for females of African
heritage, which was in greatest contrast to the result for males of non-
African heritage. The graph shows 95% confidence intervals for SOD
activity by Gender/Race combinations.
doi:10.1371/journal.pone.0018574.g002
Environmental Tobacco Smoke and Asthma
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A longitudinal study of Seventh-day Adventists in the United
States reports an odds ratio of 1.45 for asthma in relation to 10
years of exposure to ETS in the workplace [45]. Observational
studies suggest that ETS exposure is related to more severe airflow
obstruction in adult asthmatics [22,46,47]. In addition, experi-
mental studies identify acute effects of ETS on lung function of
adults with established asthma [8,29,48,49,50,51]. Some studies
have suggested that the effect of ETS exposure may be gender
related [43,52]. Xu et al showed that in sex-specific regression
analyses, effects of ETS appeared more pronounced in men than
in women, though the interaction of gender and ETS was not
statistically significantly [53]. In this study, no gender difference
was found in the association between ETS and lung functions,
which is in agreement with the European Community Respiratory
Health Survey (ECRGH) [14].
Passive or active cigarette smoke is injurious to the lower
respiratory tract by increasing the oxidant burden [31] and
reducing levels of nonenzymatic antioxidants, such as vitamin C
[54], and carotenoids [54,55,56]. Nitrosative stress characteristic
of cigarette smoke can inhibit the activity of at least one SOD
isoform through tyrosine nitration [57,58], though other mecha-
nisms may be operative as well. Consistent with our findings,
Aycicek et al reported that ETS exposure leads to a decrease of
total serum antioxidant capacity, which measures the total amount
of radicals that can be scavenged by nonenzymatic antioxidants
[59]. To our knowledge, however, this study is the first report
demonstrating lower levels of specific enzymatic activity in the
blood of asthmatic individuals exposed to ETS. While we do not
discriminate the SOD form affected in this report, the protein
levels of CuZnSOD and MnSOD among the ETS and non-ETS
asthmatics were not significantly different (all p.0.05, data not
shown). This is consistent with prior studies that showed loss of
SOD activity in lungs of asthmatics without a decrease in protein
expression, i.e. loss of activity is related to protein inactivation
[6,7,32,60]. The association of ETS effect on SOD activity in
asthmatic women of African heritage in this study implies the
possibility of a genotype-environment-phenotype interaction. In
support of this concept, previous study has shown a positive
association between genetic polymorphism in the MnSOD gene
and the risk of cancer in cigarette smokers [61]. Furthermore, an
increase in EC-SOD protein in serum of individuals with smoking-
related chronic obstructive pulmonary disease (COPD) is related
to polymorphisms of the EC-SOD gene [62]. Polymorphisms are
also common in the CuZnSOD gene and associated with reduced
affinity of the enzyme for binding Zn, which leads to greater
susceptibility to oxidant damage [63]. Recent study by Arcaroli et
al. showed that polymorphisms in EC-SOD are associated with
acute lung injury and mortality [64]. Nevertheless, using
information from a Genome Wide Association Study (GWAS)
on a cohort of subjects, SOD activity had no association with
SNPs within any of the three SOD isoforms within Aftrican
American or Caucasian populations (data not shown). Further
studies are needed to determine if individual susceptibility to ETS
exposure in asthma is related to gene polymorphisms.
The American Thoracic Society guidelines define severe asthma
as asthma that requires high-dose inhaled and/or systemic
corticosteroid treatment and that, despite these interventions, is
characterized by persistent and/or life-threatening symptoms [37].
Here, we have found that ETS exposure is associated with
phenotypic features of severe asthma symptoms among those who
do not formally meet criteria for severe asthma. That is to say, the
adverse effects of ETS are most noticeable in non-severe subjects.
We speculate that changes caused by ETS in severe asthmatics
may be less evident because those patients start from a more severe
baseline. However, it is also possible that severe asthmatics avoid
or limit exposure to ETS due to the perceived or potential
deleterious effects on their health. For example, the greater
bronchial hyperresponsiveness in the ETS-exposed severe asth-
matics may lead to greater sensitivity to inhalation of irritants and
attempts to minimize exposure. Taken together with prior
epidemiologic studies [19,25,27], the present study establishes
that ETS significantly increases the adverse effects of asthma on
individuals and the health care costs associated with managing
asthmatic patients.
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